Revolution Medicines, Inc. (RVMD) Stock Forecast
RVMD analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.71 / 5 from 24 analysts
- Price target
- $257.80 average of analyst targets
- Upside to target
- +44.9% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-2.34
- 52-week range
- $52.98 – $221.15
RVMD analyst ratings
24 analystsNumber of analysts at each rating.
RVMD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RVMD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.39 | −$3.26 | −$2.07 | −$1.61 | −48.2% | 21 |
| Current fiscal year (2026) | −$9.59 | −$12.30 | −$8.21 | −$5.95 | −61.2% | 24 |
| Next fiscal year (2027) | −$5.83 | −$9.91 | −$1.92 | −$9.59 | +39.3% | 24 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RVMD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $24.1M | $0 | $53.2M | 0.0% | 21 |
| Current fiscal year (2026) | $188.4M | $0 | $354.7M | 0.0% | 24 |
| Next fiscal year (2027) | $1.27B | $614.7M | $2.40B | +573.5% | 24 |
RVMD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RVMD revenue: reported and forecast
RVMD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.97 | −$2.46 | −$2.41 | −$2.38 | −$2.39 | +20.9% | 2 up · 0 down |
| Current fiscal year (2026) | −$8.03 | −$9.56 | −$9.74 | −$9.61 | −$9.59 | +19.4% | 3 up · 0 down |
| Next fiscal year (2027) | −$5.73 | −$6.60 | −$6.08 | −$5.71 | −$5.83 | +1.6% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RVMD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RVMD beat in 2 of 12.
What analysts expect from RVMD
24 analysts cover Revolution Medicines; their consensus rating is strong buy (4.71 on a 1–5 scale, where 5 is a strong buy). The average price target is $257.80, 44.9% above the latest close of $177.96. Analysts expect earnings of −$9.59 per share for 2026, −61.2% from a year earlier. For 2027 the average estimate is −$5.83 per share on revenue of $1.3 billion. Revolution Medicines beat the EPS estimate in 2 of the last 12 quarters.
Related: RVMD income statement, RVMD key metrics, RVMD chart. See the RVMD stock overview for the latest quote and news.
RVMD forecast FAQ
What is Revolution Medicines's price target?
The average analyst price target for Revolution Medicines is $257.80, 44.9% above the latest close of $177.96.
Is Revolution Medicines a buy, hold or sell?
Of 24 analysts covering Revolution Medicines, 18 rate it a strong buy, 5 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Revolution Medicines's EPS forecast?
Analysts forecast −$9.59 per share for 2026 (range −$12.30 to −$8.21); for 2027 the estimate is −$5.83.
What is Revolution Medicines's revenue forecast?
The average revenue estimate for 2026 is $188.4 million, growth of 0.0%; for 2027 it is $1.3 billion.
When does Revolution Medicines report earnings?
Revolution Medicines is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-2.34.
Does Revolution Medicines usually beat earnings estimates?
Revolution Medicines reported EPS at or above the analyst estimate in 2 of the last 12 quarters.